By 2034, the global market for diabetes medications is projected to approach $164 billion — not because of a breakthrough, but because of a continuation. As aging populations, rising obesity, and shifting diets push type 2 diabetes prevalence steadily upward across the world, the pharmaceutical industry is positioned to grow in direct proportion to human vulnerability. This is less a story of innovation than of infrastructure: a chronic disease requiring lifelong treatment, expanding quietly into the future.